Targeting the β secretase BACE1 for Alzheimer's disease therapy - The Lancet Neurology
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease | Nature Reviews Neurology
Frontiers | Targeting Amyloidogenic Processing of APP in Alzheimer's Disease | Molecular Neuroscience
Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment - ScienceDirect
Small molecules targeting Abeta in clinical trials for Alzheimer's disease. | Download Scientific Diagram
BACE1 Inhibitors in Phase 3 Trials for Alzheimer's are Safe in Moderate Doses, According to Study - Alzheimer's News Today
Current status of anti-Alzheimer's disease drugs in trials | Download Scientific Diagram
Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease* - Journal of Biological Chemistry
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease | Alzheimer's Research & Therapy | Full Text
Expert Insights: Another Failure for BACE1 Drugs Raises Questions about Alzheimer's Disease Treatments - Clinical Trials Arena
Why BACE inhibitors may be failing Alzheimer' | EurekAlert!
Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression | Nature Communications
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients
A Close Look at BACE1 Inhibitors for Alzheimer's Disease Treatment. - Abstract - Europe PMC
Frontiers | Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment | Chemistry
BACE1 inhibitor drugs in clinical trials for Alzheimer's disease | Semantic Scholar
Alzheimer's disease: clinical trials and drug development - The Lancet Neurology
Frontiers | Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment | Chemistry
Small molecule BACE1 inhibitors in clinical trials | Download Table
Why are BACE1 inhibitors failing clinical trials?
Medicinal Chemistry in Review: BACE1 Inhibitors as a Treatment for Alzheimer's Disease | Domainex
Merck BACE1 drug fails in prodromal Alzheimer's phase 3 | Fierce Biotech
BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease - Moussa‐Pacha - 2020 - Medicinal Research Reviews - Wiley Online Library
A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer's disease | EMBO Molecular Medicine
PDF) BACE1 inhibitor drugs in clinical trials for Alzheimer's disease
